KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacific Biosciences Of California (PACB) Short term Debt (2021 - 2023)

Pacific Biosciences Of California has reported Short term Debt over the past 6 years, most recently at $96.2 million for Q3 2023.

  • For Q3 2023, Short term Debt changed N/A year-over-year to $96.2 million; the TTM value through Sep 2023 reached $96.2 million, changed N/A, while the annual FY2022 figure was $172.1 million, 10602.36% up from the prior year.
  • Short term Debt for Q3 2023 was $96.2 million at Pacific Biosciences Of California, down from $186.3 million in the prior quarter.
  • Over five years, Short term Debt peaked at $186.3 million in Q2 2023 and troughed at $1.6 million in Q4 2021.
  • A 3-year average of $128.1 million and a median of $172.1 million in 2022 define the central range for Short term Debt.
  • On a YoY basis, Short term Debt climbed as much as 10602.36% in 2022 and fell as far as 10602.36% in 2022.
  • Year by year, Short term Debt stood at $1.6 million in 2021, then soared by 10602.36% to $172.1 million in 2022, then tumbled by 44.1% to $96.2 million in 2023.
  • Business Quant data shows Short term Debt for PACB at $96.2 million in Q3 2023, $186.3 million in Q2 2023, and $184.4 million in Q1 2023.